Skip to main content
Premium Trial:

Request an Annual Quote

Affy Founder Fodor to Step Down as CEO in January; King Tapped as Successor

NEW YORK (GenomeWeb News) – Affymetrix founder, chairman, and CEO Stephen Fodor will relinquish his CEO responsibilities as of Jan. 1, 2009, the company said today.
Fodor will serve as full-time executive chairman, a position in which he will “identify and advance new platform technologies and explore new market opportunities for the company,” Affymetrix said in a statement.
Kevin King, president of Affymetrix, will become CEO and a member of the board of directors on Jan. 1.
Fodor founded Affymetrix in 1993 and served in various roles, including president, COO, and CTO, until he was appointed CEO in 1997. Fodor has served as chairman of the company’s board since 1999.
Fodor said in a statement that Affymetrix has “an exciting portfolio of next-generation technologies,” and noted that his time is “best spent identifying new technologies for the company and accelerating their development for applications in scientific research and the health care enterprise.”
Paul Berg, Nobel Laureate and a member of Affy’s board of directors, said that Fodor “has planned for an orderly management transition that began by hiring Kevin King in January 2007."

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.